Pioneering the first dedicated therapeutic for HCM

Development Timelinefor Perhexiline

Phase 3PLANNED MID-2017
Phase 2Q2 2016 - Q4 2016
Novel Monitoring AssayQ1 2016 - Q2 2016

About Heart Metabolics

Heart Metabolics Limited is pioneering a pharmaceutical therapy for hypertrophic cardiomyopathy.

HCM is an inherited heart condition in which the contracting mechanism of the heart cell is defective. This leads to deleterious heart muscle thickening and a situation in which the heart is unable to pump enough blood to the rest of the body. Although about 600,000 people in the US alone have a gene mutation that places them at risk for HCM, it often goes undiagnosed because many people with the disease have few if any symptoms and can lead normal lives with no significant problems. However, in about 20% of these people, the condition can cause symptoms which include shortness of breath with exercise, chest pain, or problems with the heart’s electrical system. Sometimes these symptoms may be severe or even fatal.